Methoden vergelijken
Bekijk de geselecteerde methoden naast elkaar; rijen die verschillen zijn gemarkeerd.
| Populatie Farmacokinetiek× | Farmacokinetisch compartimentmodel× | |
|---|---|---|
| Vakgebied | Farmacometrie | Farmacometrie |
| Familie | Regression model | Regression model |
| Jaar van ontstaan≠ | 1977 | 1982 |
| Grondlegger≠ | Sheiner, Rosenberg & Marathe | Gibaldi & Perrier |
| Type≠ | Nonlinear mixed-effects regression model | Deterministic ODE-based pharmacokinetic model |
| Oorspronkelijke bron≠ | Sheiner, L. B., Rosenberg, B., & Marathe, V. V. (1977). Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics, 5(5), 445–479. DOI ↗ | Gibaldi, M., & Perrier, D. (1982). Pharmacokinetics (2nd ed.). Marcel Dekker. ISBN: 978-0-8247-1042-2 |
| Aliassen | PopPK, Nonlinear Mixed-Effects Modeling, NONMEM Approach, Popülasyon Farmakokinetiği | Mammillary Compartment Model, Multi-Compartment PK Model, Compartmental Analysis, Farmakokinetik Kompartman Modeli |
| Verwant≠ | 2 | 3 |
| Samenvatting≠ | Population Pharmacokinetics (PopPK) is a nonlinear mixed-effects modeling framework that characterizes how drugs are absorbed, distributed, metabolized, and eliminated across a patient population, estimating both typical population parameters and the magnitude of between-subject variability. Introduced by Sheiner, Rosenberg, and Marathe in 1977, it enables parameter estimation from sparse, routinely collected clinical data—making it indispensable in drug development, regulatory submissions, and individualized dosing. | The pharmacokinetic compartment model represents the body as one or more hypothetical compartments interconnected by first-order rate processes, describing how a drug is absorbed, distributed, and eliminated over time. Systematized by Gibaldi and Perrier in 1982, these models use ordinary differential equations to characterize plasma concentration-time profiles. They are the cornerstone of drug development, dosage regimen design, and regulatory submission pharmacokinetic analyses. |
| ScholarGateGegevensset ↗ |
|
|